The Novavax vaccine targets the same XBB.1.5 variant as the other two vaccines. That variant was the dominant one in the U.S. earlier this year when the FDA had to choose the makeup of this fall's ...

Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...

The Novavax vaccine would be authorized for use in adults only in two doses. The company submitted a request, which the FDA is considering, to provide the same vaccine as a booster dose.

FDA requests new clinical trial for Novavax COVID-19 vaccine Political appointees delayed full vaccine approval process Concerns grow over stricter rules for other COVID-19 vaccines Experts warn ...

If greenlighted by the FDA, Novavax's shots could be the first COVID-19 doses available in the U.S. based on a kind of "protein subunit" technology that has been used for decades in other routine ...

The FDA on Tuesday authorized Novavax’s updated Covid-19 vaccine, giving Americans seeking to update their protection against the SARS-CoV-2 virus another option.

At the recommendation of the FDA, the new boosters protect against XBB variants, which made up 95% of all U.S. Covid cases in June.

The US Food and Drug Administration on Wednesday authorized Novavax’s Covid-19 vaccine for emergency use in adults. It is the fourth coronavirus vaccine available in the United States, and it ...

Most of the FDA’s Vaccines and Related Biological Products Advisory Committee voted “yes” in response to a question of whether the benefits of Novavax’s vaccine, given as a two-dose ...

During the review on Tuesday, the FDA's advisers pushed Novavax representatives on multiple points. Signage outside the Novavax facility in Gaithersburg, Md., May 18, 2022.

The FDA was on track to grant Novavax full approval by its April 1 target date, according to two people with direct knowledge of the situation who spoke on condition of anonymity to discuss ...

“Today’s FDA emergency use authorization of our COVID-19 vaccine provides the U.S. with access to the first protein-based COVID-19 vaccine,” said Stanley C. Erck, Novavax’s CEO.